Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
We report a patient with BCR-ABL1 fusion positive T-cell ALL with a previously undescribed cell distribution of the fusion gene.
|
31136068 |
2019 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Approximately 8% of childhood T-ALL cases have rearrangements involving the ABL1 tyrosine kinase gene at 9q34.12; although a t(9;22), resulting in a fusion of ABL1 with the BCR gene at 22q11.23 is a common occurrence in B-ALL, it is not a typical finding in T-ALL.
|
30803551 |
2019 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.600 |
FusionGene
|
disease |
ORPHANET |
Identification of fusion genes and characterization of transcriptome features in T-cell acute lymphoblastic leukemia.
|
29279377 |
2018 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
In conclusion, this work identifies LCK, MAD2L1, NUP155 and SMC4 as four new potential drug targets in NUP214-ABL1-positive T-cell acute lymphoblastic leukemia.
|
23872305 |
2014 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
We describe a pediatric case of T-cell ALL with amplification of the ABL1 gene in which remission was achieved only after the addition of dasatinib to conventional chemotherapy.
|
22689211 |
2012 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Screening for ABL1 chimeric genes could be performed in patients with ALL, more particularly in those with T-cell ALL because ABL1 modulates T-cell development and plays a role in cytoskeletal remodeling processes in T cells.
|
21435002 |
2011 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The most frequent and strictly associated with T-ALL is the NUP214-ABL1 fusion identified in 6% of cases, in both children and adults.
|
20073070 |
2010 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
High-WT1/high-MDR1 mRNA expression was strongly associated with BCR-ABL expression and a higher tendency to be T-cell ALL type.
|
20423567 |
2010 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Heterogeneous patterns of amplification of the NUP214-ABL1 fusion gene in T-cell acute lymphoblastic leukemia.
|
18923437 |
2009 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Although a number of collaborating genetic events have been identified in TLX3 rearranged T-ALL patients (NOTCH1 mutations, p15/p16 deletions, NUP214-ABL1 amplifications), further elucidation of additional genetic lesions could provide a better understanding of the pathogenesis of this specific T-ALL subtype.
|
18185524 |
2008 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
The NUP214-ABL1 fusion kinase has recently been identified in 6% of patients with T-cell acute lymphoblastic leukemia.
|
18784740 |
2008 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Moreover, dasatinib was active in a NUP214-ABL1-positive leukemia xenograft murine model and in marrow lymphoblasts from a patient with NUP214-ABL1-positive T-ALL.
|
18401417 |
2008 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Likewise, the frequency and the prognostic significance in pediatric T-cell acute lymphoblastic leukemia of the newly characterized NUP214-ABL1 fusion transcript is not yet clear.
|
18835836 |
2008 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
NOTCH1 mutations were identified in all T-cell acute lymphoblastic leukemia patients with ABL1 fusions and in a T-cell acute lymphoblastic leukemia cell line expressing NUP214-ABL1.
|
18322257 |
2008 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
In order to establish the incidence of ABL1 overexpression in T-ALL, we evaluated 17 additional patients by quantitative (Q)-polymerase chain reaction (PCR) and reverse transcription (RT)-PCR.
|
17488685 |
2007 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
We describe a case of coexisting BCR-ABL negative myeloproliferative disorder and precursor T-cell lymphoblastic lymphoma associated with t(8;13) involving FGFR1 at 8p11 in a 14-year-old boy who presented with generalized lymphadenopathy and an abdominal mass.
|
16777224 |
2007 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
ABL gene amplification and NOTCH1 gene mutations in subsets of pre-T ALL/LBL suggest patients may benefit from therapy with tyrosine kinase and gamma-secretase inhibitors, respectively.
|
17369128 |
2007 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
DEK-CAN and CAN-ABL1 are associated with acute myeloid leukemia and T-cell acute lymphoblastic leukemia, respectively, whereas SET-CAN was identified in a patient with acute undifferentiated leukemia.
|
17569777 |
2007 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
The NUP214-ABL1 fusion gene in T-cell acute lymphoblastic leukemia (T-ALL) has recently been identified as a possible target for imatinib and related tyrosine kinase inhibitors, but exact data regarding the prognostic impact and frequency of the several putative NUP214-ABL1 mRNA transcripts are still missing.
|
16873673 |
2006 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
We reached the following conclusions: (1) FISH is the only technique that promptly identifies T-cell ALL patients with ABL1 amplification, (2) quick identification with FISH is fundamental in the clinic because this T-cell ALL subset is imatinib sensitive but may become resistant due to development of additional mutations, and (3) ABL1 quantitative RT-PCR may be easily applied to monitor minimal residual disease.
|
16213363 |
2005 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
These data further demonstrate the involvement of ABL1 fusions in the pathogenesis of T-ALL and identify EML1-ABL1 as a novel therapeutic target of imatinib.
|
15713800 |
2005 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The authors herein describe an 8-year-old male patient with precursor T-cell ALL harboring both ABL gene amplification and p16(INK4a) gene deletion.
|
15282669 |
2004 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
NUP214-ABL1 expression defines a new subgroup of individuals with T-ALL who could benefit from treatment with imatinib.
|
15361874 |
2004 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Here, we describe one adult with chronic myeloid leukemia and a child with T-cell acute lymphocytic leukemia with ETV6/ABL1.
|
11170285 |
2001 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Molecular detection of a late-appearing BCR-ABL gene in a child with T-cell acute lymphoblastic leukemia.
|
9760154 |
1998 |